Financial

GrayMatters Health Announces New Research Expanding Scientific Validity and Clinical Impact of fMRI-Informed Biomarkers

Findings bridge groundbreaking science with real-world clinical practiceNEW YORK, Jan. 13, 2026 /PRNewswire/ -- GrayMatters Health (GMH), the pioneers of digital...

Freenome Announces Expanded Artificial Intelligence and Deep Learning Initiatives Accelerated by NVIDIA, to Advance Personalized Multi-Cancer Detection

– Collaboration is designed to improve analytical speed and accuracy of Freenome's blood-based cancer screening tests – BRISBANE, Calif., Jan. 12, 2026...

Doceree Emerges as Healthcare Marketing’s Most AI-Forward Technology Platform, Building Industry’s First Operating System for the AI Era

Company unifies its AI ecosystem under doceree.ai, launches five industry-first AI solutions, earns top global recognitions, and defines the 2026...

InterVenn Biosciences Partners with Aranscia to Accelerate Commercialization of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test

Aranscia's Suite of Laboratory and Technology Solutions to Support InterVenn's Commercialization ProgramSOUTH SAN FRANCISCO, Calif. and HOUSTON, Jan. 7, 2026...

InterVenn Biosciences Partners with Aranscia to Accelerate Commercialization of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test

Aranscia's Suite of Laboratory and Technology Solutions to Support InterVenn's Commercialization ProgramSOUTH SAN FRANCISCO, Calif. and HOUSTON, Jan. 7, 2026...

InterVenn Biosciences Partners with Aranscia to Accelerate Commercialization of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test

Aranscia's Suite of Laboratory and Technology Solutions to Support InterVenn's Commercialization ProgramSOUTH SAN FRANCISCO, Calif. and HOUSTON, Jan. 7, 2026...

error: Content is protected !!